JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.28% |
| 2 | Technology | 15.04% |
| 3 | Healthcare | 12.52% |
| 4 | Financials | 10.55% |
| 5 | Consumer Discretionary | 7.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5001
Tarsus Pharmaceuticals
TARS
$3.53B
| $142K | ﹤0.01% |
9,693
+5,739
| +145% | +$86.2K |
2020 Q4
6 quarters
|
|
|
PEAR
5002
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $142K | ﹤0.01% |
91,969
+90,569
| +6,469% | +$354K |
2022 Q1
1 quarter
|
|
5003
PUT
Glaukos
GKOS
$9.62B
| $141K | ﹤0.01% |
+3,100
| New | +$147K |
2022 Q2
0 quarters
|
|
5004
Braze
BRZE
$2.91B
| $140K | ﹤0.01% |
+3,870
| New | +$141K |
2022 Q2
0 quarters
|
|
5005
Lifecore Biomedical
LFCR
$248M
| $140K | ﹤0.01% |
14,008
+1,743
| +14% | +$17.3K |
2017 Q4
18 quarters
|
|
5006
Aura Biosciences
AURA
$626M
| $139K | ﹤0.01% |
9,798
+7,170
| +273% | +$119K |
2021 Q4
2 quarters
|
|
5007
Barclays
BCS
$79.2B
| $139K | ﹤0.01% |
18,190
-150,075
| -89% | -$1.18M |
2013 Q2
36 quarters
|
|
5008
Blue Ridge Bankshares
BRBS
$347M
| $139K | ﹤0.01% |
9,101
+965
| +12% | +$14.3K |
2021 Q2
4 quarters
|
|
5009
Franklin FTSE United Kingdom ETF
FLGB
$841M
| $139K | ﹤0.01% |
6,250
+3,981
| +175% | +$95.9K |
2022 Q1
1 quarter
|
|
5010
PUT
KB Home
KBH
$2.83B
| $139K | ﹤0.01% |
+4,900
| New | +$156K |
2022 Q2
0 quarters
|
|
5011
TriplePoint Venture Growth BDC
TPVG
$199M
| $139K | ﹤0.01% |
10,905
+8,605
| +374% | +$130K |
2017 Q1
21 quarters
|
|
|
BEST
5012
DELISTED
BEST Inc. American Depositary Shares, each representing twenty (20) Class A Ordinary Shares
BEST
| $139K | ﹤0.01% |
29,487
-3,080
| -9% | -$21.6K |
2017 Q3
19 quarters
|
|
5013
Donegal Group Class A
DGICA
$674M
| $138K | ﹤0.01% |
8,134
-4,529
| -36% | -$67.9K |
2017 Q4
18 quarters
|
|
5014
1-800-Flowers.com
FLWS
$164M
| $138K | ﹤0.01% |
14,478
-257,045
| -95% | -$2.84M |
2017 Q4
18 quarters
|
|
5015
Schwab Fundamental US Small Company Index ETF
FNDA
$8.66B
| $138K | ﹤0.01% |
6,100
+594
| +11% | +$14.7K |
2018 Q2
16 quarters
|
|
5016
HighPeak Energy
HPK
$1B
| $138K | ﹤0.01% |
5,375
+2,664
| +98% | +$77.5K |
2021 Q1
5 quarters
|
|
5017
John Hancock Multifactor Mid Cap ETF
JHMM
$5.9B
| $138K | ﹤0.01% |
3,123
+965
| +45% | +$46.7K |
2021 Q2
4 quarters
|
|
|
BRT
5018
BRT Apartments
BRT
$250M
| $137K | ﹤0.01% |
6,390
-4,324
| -40% | -$95.3K |
2018 Q2
16 quarters
|
|
|
BTAI
5019
DELISTED
BioXcel Therapeutics
BTAI
| $137K | ﹤0.01% |
649
-201
| -24% | -$42.3K |
2019 Q2
12 quarters
|
|
5020
Bankwell Financial Group
BWFG
$523M
| $137K | ﹤0.01% |
4,409
-1,974
| -31% | -$66.4K |
2017 Q4
18 quarters
|
|
5021
Exchange Listed Funds Trust ETC Cabana Target Leading Sector Moderate ETF
CLSM
$98.2M
| $137K | ﹤0.01% |
+6,421
| New | +$142K |
2022 Q2
0 quarters
|
|
5022
INVE Technologies, Inc. Common Stock
INVE
$57.9M
| $137K | ﹤0.01% |
11,814
+1,718
| +17% | +$21.5K |
2021 Q2
4 quarters
|
|
5023
John Marshall Bancorp
JMSB
$323M
| $137K | ﹤0.01% |
+6,092
| New | +$158K |
2022 Q2
0 quarters
|
|
5024
Park Aerospace
PKE
$646M
| $137K | ﹤0.01% |
10,725
+1,158
| +12% | +$14.2K |
2014 Q4
30 quarters
|
|
|
VWE
5025
DELISTED
Vintage Wine Estates, Inc. Common Stock
VWE
| $137K | ﹤0.01% |
17,453
-58,656
| -77% | -$540K |
2021 Q4
2 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,728 reduced and 609 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 609 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.